Phase III ALINA study: Alecensa reduces risk of disease recurrence/death in NSCLC

FDA approves inavolisib + palbociclib + fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer

FDA approved Itovebi (inavolisib) with palbociclib (Ibrance) and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth-factor receptor 2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.

October 11, 2024

Vol.50 No.38

Drugs & Targets

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

FDA approved Opdivo (nivolumab) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent Opdivo after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Rybrevant + chemo shows improved OS data in NSCLC

Updated results from the phase III MARIPOSA-2 study showed Rybrevant (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated NSCLC with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Friends publishes evaluation of RWE in NSCLC

Findings by Friends of Cancer Research were published recently in JCO Clinical Cancer Informatics in a paper titled “Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy.”

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

September 06, 2024

Vol.50 No.33

Phase III ALINA study: Alecensa reduces risk of disease recurrence/death in NSCLC

YOU MAY BE INTERESTED IN

FDA approves inavolisib + palbociclib + fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

Rybrevant + chemo shows improved OS data in NSCLC

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

Friends publishes evaluation of RWE in NSCLC

FDA approves Rybrevant + Lazcluze for NSCLC

Renew today!

Subscriber content

Login